Obermatt

DongKook Pharmaceutical

KOE:086450 · KR7086450004
PharmaceuticalsSmall

360

93
EV / EBIT78
Price / Owner Earnings17
Owner Earnings Yield68
Dividend Yield71
Price/Sales78
EV / Gross Profit89
Price/Book54
Return on Capital83
Cash Return on Capital70
Return on Equity77
EBIT Margin70
Gross Profitability87
Cash Conversion43
Accruals38
Owner Earnings Margin57
Sales growth66
Profit Growth56
Long-Term EPS Growth57
Owner Earnings Growth34
Reinvestment69
Price momentum73
Debt load80
Refinancing60
Debt Payback100
Liquidity94
Analyst ratings100
Opinion Changes50
Price Target Upside69
Market mood4
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

DongKook Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSDAQ
Founded1968
Employees21
ISINKR7086450004
Last UpdateApr 2, 2026
Index & Theme
UrologyDiabetesImmunologyEndocrinologyGastroenterologyCardiovascularNeurologyInfectious DiseasesOsteoporosisOncologyObesityHepatologyBiotechnologyManufacturingPharmaceutical

Description

DongKook Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products, including both prescription and over-the-counter medications. The company focuses on providing high-quali…

Analysis

Middle-of-the-road

DongKook Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.4×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
98
2023202420252026

All-time high

100

Mar 2026

All-time low

86

Jan 2025

Average rank

94

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
78
78
78
61
Price/Earnings
72
72
72
62
Price/Book
54
38
51
34
Dividend Yield
71
37
46
32
Value (overall)
80
56
66
49

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare DongKook Pharmaceutical with its peers
Korea United Pharm
KSC:033270
90
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samsung Pharm
KSC:001360
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Towa Pharmaceutical
TYO:4553
50
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
ST Pharm
KOE:237690
86
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →